ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Athira Pharma Inc

Athira Pharma Inc (ATHA)

0.529
0.0099
(1.91%)
마감 30 1월 6:00AM
0.529
0.00
( 0.00% )
시간외 단일가: 6:50PM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
0.529
매수가
0.50
매도가
0.56
거래량
-
0.00 일간 변동폭 0.00
0.4115 52주 범위 4.2984
market_cap
전일 종가
0.529
개장가
-
최근 거래 시간
마지막 거래 시간
-
재정 규모
-
VWAP
-
평균 볼륨(3m)
432,144
발행 주식
38,669,073
배당수익률
-
주가수익률
-0.17
주당순이익(EPS)
-3.04
매출
1.63M
순이익
-117.67M

Athira Pharma Inc 정보

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease. Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Athira Pharma Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker ATHA. The last closing price for Athira Pharma was US$0.53. Over the last year, Athira Pharma shares have traded in a share price range of US$ 0.4115 to US$ 4.2984.

Athira Pharma currently has 38,669,073 shares in issue. The market capitalisation of Athira Pharma is US$20.46 million. Athira Pharma has a price to earnings ratio (PE ratio) of -0.17.

ATHA 최신 뉴스

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.0193-3.519970818890.54830.570.50052742980.5263636CS
4-0.0648-10.91276524080.59380.6080.50051978650.54411915CS
12-0.181551-25.55073457080.7105510.82640.50054321440.6495934CS
26-2.911-84.62209302333.443.670.411527390080.6430532CS
52-2.741-83.82262996943.274.29840.411514930920.83115141CS
156-9.451-94.69939879769.9814.220.41157349771.87601809CS
260-19.421-97.348370927319.9534.790.41156658545.09290089CS

ATHA - Frequently Asked Questions (FAQ)

What is the current Athira Pharma share price?
The current share price of Athira Pharma is US$ 0.529
How many Athira Pharma shares are in issue?
Athira Pharma has 38,669,073 shares in issue
What is the market cap of Athira Pharma?
The market capitalisation of Athira Pharma is USD 20.46M
What is the 1 year trading range for Athira Pharma share price?
Athira Pharma has traded in the range of US$ 0.4115 to US$ 4.2984 during the past year
What is the PE ratio of Athira Pharma?
The price to earnings ratio of Athira Pharma is -0.17
What is the cash to sales ratio of Athira Pharma?
The cash to sales ratio of Athira Pharma is 12.59
What is the reporting currency for Athira Pharma?
Athira Pharma reports financial results in USD
What is the latest annual turnover for Athira Pharma?
The latest annual turnover of Athira Pharma is USD 1.63M
What is the latest annual profit for Athira Pharma?
The latest annual profit of Athira Pharma is USD -117.67M
What is the registered address of Athira Pharma?
The registered address for Athira Pharma is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Athira Pharma website address?
The website address for Athira Pharma is www.athira.com
Which industry sector does Athira Pharma operate in?
Athira Pharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ATHEAlterity Therapeutics Limited
US$ 6.10
(109.62%)
2.27M
NAOVNanoVibronix Inc
US$ 0.666
(73.66%)
24.13M
CFSBCFSB Bancorp Inc
US$ 12.00
(57.27%)
6
GDEVGDEV Inc
US$ 24.99
(56.29%)
1
RBBRBB Bancorp
US$ 29.99
(54.03%)
8
CLEUChina Liberal Education Holdings Ltd
US$ 1.81
(-76.65%)
609.6k
CRGXCARGO Therapeutics Inc
US$ 3.38
(-74.37%)
541.4k
FKWLFranklin Wireless Corporation
US$ 3.00
(-42.42%)
510
ECBKECB Bancorp Inc
US$ 8.01
(-41.49%)
5
FBLAFB Bancorp Inc
US$ 7.01
(-40.34%)
7
NAOVNanoVibronix Inc
US$ 0.666
(73.66%)
24.13M
MGOLMGO Global Inc
US$ 0.127
(24.88%)
20.6M
XFORX4 Pharmaceuticals Inc
US$ 0.8387
(14.08%)
12.1M
RIMEAlgorhythm Holdings Inc
US$ 0.0246
(-5.38%)
4.28M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 26.20
(5.94%)
4.17M

ATHA Discussion

게시물 보기
Rocket-Interceptor Rocket-Interceptor 3 월 전
just amazing
👍️0
glenn1919 glenn1919 3 월 전
ATHA................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 월 전
ATHA...........................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 월 전
ATHA TO A DOLLAR
👍️0
glenn1919 glenn1919 3 월 전
ATHA...........................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️ 1
stockyupydowny stockyupydowny 5 월 전
Some life coming back into play with this one, the 400 million cash injection deal that takes the to the $1 billion dollar deal they made will be reflected with patience
👍️ 1
Saving Grace Saving Grace 5 월 전
ATHA under .65 cents and plunging.
👍️0
Monksdream Monksdream 5 월 전
ATHA under $4
👍️0
Monksdream Monksdream 6 월 전
ATHA under $3
👍️0
Monksdream Monksdream 8 월 전
ATHA under $3
👍️0
glenn1919 glenn1919 10 월 전
ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 11 월 전
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
👍️0
Whalatane Whalatane 11 월 전
4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi
👍️0
Whalatane Whalatane 1 년 전
“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”


Kiwi
👍️0
Whalatane Whalatane 1 년 전
ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi
👍️0
Whalatane Whalatane 1 년 전
The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA... what a bio beast running through the streets...watch the explosion on the horizon...
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
What a day…what a stock!!!
👍️0
great_tree great_tree 3 년 전
Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA pushing hard into close
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA bio beast is very mad. She wants to fill that gap
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA is ready to move big next week, the best bio taking on Alzheimers
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA starting to heat up..love this bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA another bio beast ready to beast
👍️0
maximumgriff maximumgriff 4 년 전
Girt prices
👍️0
crudeoil24 crudeoil24 4 년 전
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
👍️0
crudeoil24 crudeoil24 4 년 전
Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.
👍️0

최근 히스토리

Delayed Upgrade Clock